399 related articles for article (PubMed ID: 16400431)
1. [Non-functioning pituitary adenomas: clinical features and immunohistochemistry].
Ferreira JE; de Mello PA; de Magalhães AV; Botelho CH; Naves LA; Nosé V; Schmitt F
Arq Neuropsiquiatr; 2005 Dec; 63(4):1070-8. PubMed ID: 16400431
[TBL] [Abstract][Full Text] [Related]
2. Ki-67 labeling index and expression of p53 are non-predictive for invasiveness and tumor size in functional and nonfunctional pituitary adenomas.
Grimm F; Maurus R; Beschorner R; Naros G; Stanojevic M; Gugel I; Giese S; Bier G; Bender B; Honegger J
Acta Neurochir (Wien); 2019 Jun; 161(6):1149-1156. PubMed ID: 31037500
[TBL] [Abstract][Full Text] [Related]
3. Clinical tumor growth and comparison with proliferation markers in non-functioning (inactive) pituitary adenomas.
Saeger W; Lüdecke B; Lüdecke DK
Exp Clin Endocrinol Diabetes; 2008 Feb; 116(2):80-5. PubMed ID: 18072009
[TBL] [Abstract][Full Text] [Related]
4. Expression of p53, Ki-67 and c-erb B2 in growth hormone-and/or prolactin-secreting pituitary adenomas.
Botelho CH; Magalhães AV; Mello PA; Schmitt FC; Casulari LA
Arq Neuropsiquiatr; 2006 Mar; 64(1):60-6. PubMed ID: 16622555
[TBL] [Abstract][Full Text] [Related]
5. Proliferation markers in different types of clinically non-secreting pituitary adenomas.
Schreiber S; Saeger W; Lüdecke DK
Pituitary; 1999 May; 1(3-4):213-20. PubMed ID: 11081200
[TBL] [Abstract][Full Text] [Related]
6. Atypical pituitary adenomas: clinical characteristics and role of ki-67 and p53 in prognostic and therapeutic evaluation. A series of 50 patients.
Del Basso De Caro M; Solari D; Pagliuca F; Villa A; Guadagno E; Cavallo LM; Colao A; Pettinato G; Cappabianca P
Neurosurg Rev; 2017 Jan; 40(1):105-114. PubMed ID: 27215912
[TBL] [Abstract][Full Text] [Related]
7. The Prognostic Roles of the Ki-67 Proliferation Index, P53 Expression, Mitotic Index, and Radiological Tumor Invasion in Pituitary Adenomas.
Hasanov R; Aydoğan Bİ; Kiremitçi S; Erden E; Güllü S
Endocr Pathol; 2019 Mar; 30(1):49-55. PubMed ID: 30610566
[TBL] [Abstract][Full Text] [Related]
8. Overexpression of prothymosin alpha is related to pituitary adenoma recurrence but not to adenoma invasiveness and proliferation.
Pawlikowski M; Radek M; Kunert-Radek J; Jaranowska M; Świętosławski J; Winczyk K
Endokrynol Pol; 2014; 65(5):382-6. PubMed ID: 25301489
[TBL] [Abstract][Full Text] [Related]
9. Typical and atypical pituitary adenomas: a single-center analysis of outcome and prognosis.
Chiloiro S; Doglietto F; Trapasso B; Iacovazzo D; Giampietro A; Di Nardo F; de Waure C; Lauriola L; Mangiola A; Anile C; Maira G; De Marinis L; Bianchi A
Neuroendocrinology; 2015; 101(2):143-50. PubMed ID: 25633744
[TBL] [Abstract][Full Text] [Related]
10. Cystic versus non-cystic silent corticotrophic adenomas: clinical and histological analysis of 62 cases after microscopic transsphenoidal surgery-a retrospective, single-center study.
Sumislawski P; Huckhagel T; Krajewski KL; Aberle J; Saeger W; Flitsch J; Rotermund R
Sci Rep; 2023 Feb; 13(1):2468. PubMed ID: 36774403
[TBL] [Abstract][Full Text] [Related]
11. Pituitary tumor transforming gene and insulin-like growth factor 1 receptor expression and immunohistochemical measurement of Ki-67 as potential prognostic markers of pituitary tumors aggressiveness.
Sánchez-Tejada L; Sánchez-Ortiga R; Moreno-Pérez O; Montañana CF; Niveiro M; Tritos NA; Alfonso AM
Endocrinol Nutr; 2013; 60(7):358-67. PubMed ID: 23416216
[TBL] [Abstract][Full Text] [Related]
12. Galectin-3 expression in pituitary adenomas as a marker of aggressive behavior.
Righi A; Morandi L; Leonardi E; Farnedi A; Marucci G; Sisto A; Frank G; Faustini-Fustini M; Zoli M; Mazzatenta D; Agati R; Foschini MP
Hum Pathol; 2013 Nov; 44(11):2400-9. PubMed ID: 24007691
[TBL] [Abstract][Full Text] [Related]
13. Minichromosome maintenance protein 7 as prognostic marker of tumor aggressiveness in pituitary adenoma patients.
Coli A; Asa SL; Fadda G; Scannone D; Chiloiro S; De Marinis L; Lauretti L; Ranelletti FO; Lauriola L
Eur J Endocrinol; 2016 Mar; 174(3):307-14. PubMed ID: 26620390
[TBL] [Abstract][Full Text] [Related]
14. Lack of correlation between Ki-67 labelling index and tumor size of anterior pituitary adenomas.
Mastronardi L; Guiducci A; Puzzilli F
BMC Cancer; 2001; 1():12. PubMed ID: 11570981
[TBL] [Abstract][Full Text] [Related]
15. Labeling index in pituitary adenomas evaluated by means of MIB-1: is there a prognostic role? A critical review.
de Aguiar PH; Aires R; Laws ER; Isolan GR; Logullo A; Patil C; Katznelson L
Neurol Res; 2010 Dec; 32(10):1060-71. PubMed ID: 20483025
[TBL] [Abstract][Full Text] [Related]
16. Relationship of a new histological categorization of ductal carcinoma in situ of the breast with size and the immunohistochemical expression of p53, c-erb B2, bcl-2, and ki-67.
Mack L; Kerkvliet N; Doig G; O'Malley FP
Hum Pathol; 1997 Aug; 28(8):974-9. PubMed ID: 9269835
[TBL] [Abstract][Full Text] [Related]
17. Expression of the c-erb-B2 and p53 protein in gallbladder carcinomas.
Kim YW; Huh SH; Park YK; Yoon TY; Lee SM; Hong SH
Oncol Rep; 2001; 8(5):1127-32. PubMed ID: 11496329
[TBL] [Abstract][Full Text] [Related]
18. A clinicopathological and immunohistochemical study of clinically non-functioning pituitary adenomas: a single institutional experience.
Rishi A; Sharma MC; Sarkar C; Jain D; Singh M; Mahapatra AK; Mehta VS; Das TK
Neurol India; 2010; 58(3):418-23. PubMed ID: 20644271
[TBL] [Abstract][Full Text] [Related]
19. Cyclins D1 and D3 and topoisomerase II alpha in inactive pituitary adenomas.
Saeger W; Schreiber S; Lüdecke DK
Endocr Pathol; 2001; 12(1):39-47. PubMed ID: 11478267
[TBL] [Abstract][Full Text] [Related]
20. Pituitary macroadenomas (>3 cm) in young adulthood: Pathologic and proliferative characteristics.
Öngürü Ö; Düz B; Şimşek H; Günal A; Gönül E
Neurol Neurochir Pol; 2015; 49(4):212-6. PubMed ID: 26188936
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
